Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BREVITAL SODIUM vs MICRAININ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Brevital sodium (methohexital) is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride ion influx and hyperpolarizing neurons, leading to rapid sedation and anesthesia.
MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
Induction and maintenance of general anesthesia,Adjunct to regional anesthesia,Short-duration surgical procedures
Tension headache,Migraine (off-label),Muscle contraction headache
Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15 seconds; maintenance: 0.5-1 mg/kg IV bolus as needed or 50-150 mcg/kg/min IV infusion.
2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.
Terminal elimination half-life: 3–6 hours (mean ~4 hours); prolonged in hepatic impairment, obesity, or with repeated dosing due to redistribution.
Terminal elimination half-life 8-12 hours; in elderly or severe renal impairment, may extend to 24 hours
Hepatic metabolism primarily by CYP2C9 and CYP3A4 to inactive metabolites; less than 1% excreted unchanged in urine.
Acetaminophen is primarily metabolized in the liver via glucuronidation and sulfation; a minor pathway via CYP2E1 and CYP3A4 produces the toxic metabolite NAPQI. Butalbital is extensively metabolized by CYP2C19 and other hepatic enzymes.
Primarily hepatic biotransformation to inactive metabolites (mainly hydroxy-methohexital), with renal excretion of metabolites; less than 1% excreted unchanged in urine. Minor biliary/fecal elimination.
Primarily renal (70% unchanged, 20% as sulfate conjugate); biliary/fecal <10%
Approximately 70–90% bound to albumin.
70-80% bound to albumin
Vd: 1.1–2.5 L/kg (mean ~1.5 L/kg). Larger Vd indicates extensive tissue distribution (highly lipophilic), leading to rapid redistribution and short duration after single bolus.
0.3-0.5 L/kg; indicates moderate distribution into total body water
IV: 100%. IM: Not well established; likely >90%. Rectal: Variable, ~50–70% due to first-pass metabolism and incomplete absorption.
Oral: 60-70% (due to first-pass metabolism); Intramuscular: 75-85%; Intravenous: 100%
No dosage adjustment required for GFR ≥10 m L/min; for GFR <10 m L/min, reduce dose by 50%.
Not studied; use caution with Cr Cl <30 m L/min. Avoid if severe renal impairment (Cr Cl <15 m L/min) due to acetaminophen and dichloralphenazone accumulation. No specific dose adjustment guidelines available.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75% or consider alternative.
Contraindicated in severe hepatic impairment (Child-Pugh C). In moderate impairment (Child-Pugh B), reduce dose by 50% or increase dosing interval. In mild impairment (Child-Pugh A), no adjustment necessary but monitor.
Induction: 1-2 mg/kg IV; maintenance: 0.5-1 mg/kg IV bolus or 50-150 mcg/kg/min IV infusion. Contraindicated in infants <2 months with stable BSA.
Not recommended for pediatric patients due to lack of safety and efficacy data; alternative agents preferred.
Reduce induction dose by 50% and administer slowly over 60 seconds; maintenance infusion rates at lower end (50-100 mcg/kg/min).
Use with caution due to increased sensitivity to anticholinergic effects, sedation, and hepatotoxicity. Initiate at lower doses (e.g., 1 tablet at onset) and titrate slowly. Monitor renal and hepatic function.
None.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Respiratory depression and apnea may occur; resuscitative equipment must be available,Hypotension and bradycardia possible; use with caution in patients with cardiovascular disease,Extravasation causes tissue necrosis; avoid intra-arterial injection,Seizures may occur in epileptic patients,Rapid injection may cause severe respiratory depression
Hepatotoxicity: Severe liver injury may occur with acetaminophen, especially with chronic use or doses >4000 mg/day. Monitor liver function. Dependence: Butalbital can cause tolerance and dependence; withdrawal symptoms may occur upon abrupt discontinuation. CNS depression: May impair mental and physical abilities; caution with alcohol or other CNS depressants. Renal impairment: Use with caution in patients with severe renal disease.
Known hypersensitivity to barbiturates,Porphyria (may precipitate acute attacks),Severe respiratory insufficiency,Status asthmaticus,Hypovolemic shock or severe hypotension
Hypersensitivity to acetaminophen, butalbital, or any component; porphyria; severe hepatic impairment; history of barbiturate dependence.
No specific food interactions are documented for BREVITAL SODIUM. However, patients should avoid heavy meals before anesthesia due to risk of aspiration. Do not consume alcohol or grapefruit juice for 24 hours before and after administration, as they may alter drug metabolism and increase sedation.
Avoid excessive caffeine intake from coffee, tea, soda, or chocolate as it may increase caffeine-related side effects. Grapefruit juice may potentiate effects; limit consumption. Alcohol increases risk of drowsiness and hepatotoxicity.
Teratogenic potential not fully established in humans. In animal studies, methohexital caused fetal resorptions and malformations at maternally toxic doses. First trimester: Avoid unless essential; risk of neural tube defects cannot be excluded. Second trimester: Limited data, but may cause fetal depression if used near delivery. Third trimester: Crosses placenta; may cause neonatal respiratory depression, hypotonia, and prolonged sedation. Use only if clearly needed with lowest effective dose.
MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, particularly neural tube defects, when used in the first trimester. Chronic use in the third trimester can lead to neonatal withdrawal syndrome and floppy infant syndrome. Acetaminophen is generally considered low risk at therapeutic doses. Caffeine in moderate amounts is not strongly associated with major malformations, but high doses may increase risk of miscarriage.
Excretion into human milk unknown. M/P ratio not determined. Due to short half-life, minimal transfer expected after a single dose. Caution with repeated doses or prolonged infusion. Monitor infant for sedation, feeding difficulties, or respiratory depression.
Butalbital is excreted into breast milk; the milk-to-plasma ratio is approximately 0.3-0.6. Infants are at risk of sedation, poor feeding, and withdrawal. Acetaminophen is excreted in low amounts (M/P ~0.2-0.9) and is considered compatible. Caffeine is excreted in breast milk (M/P ~0.5) and may cause irritability in infants. Use of MICRAININ during breastfeeding is generally not recommended due to butalbital.
Pregnancy may increase volume of distribution and clearance, potentially requiring higher initial doses, but the induction dose typically unchanged. Reduced doses may be needed in preeclampsia or cesarean section due to enhanced sensitivity. No specific dose adjustment guidelines; titrate to effect with careful monitoring.
No specific pharmacokinetic data for MICRAININ during pregnancy. Pregnancy can alter metabolism of acetaminophen and caffeine. Butalbital clearance may increase due to enhanced hepatic metabolism. However, dose adjustments are not typically recommended. Use the lowest effective dose for the shortest duration.
BREVITAL SODIUM (methohexital) is an ultrashort-acting barbiturate used for induction of anesthesia and for short procedures. Due to its rapid onset and brief duration, it requires careful titration. It is contraindicated in patients with porphyria. Extravasation causes tissue necrosis; administer only through a secure IV line. It lowers seizure threshold, but can also be used for electroconvulsive therapy (ECT) to induce seizures. Respiratory depression and hypotension are dose-dependent; have resuscitation equipment ready. Avoid in patients with severe hepatic impairment. Coadministration with opioids or benzodiazepines potentiates sedation and respiratory depression.
MICRAININ is a fixed-dose combination of butalbital, acetaminophen, and caffeine, used for tension-type headache. Butalbital is a barbiturate with abuse potential; limit quantity prescribed. Acetaminophen hepatotoxicity risk with >3000 mg/day. Caffeine may exacerbate anxiety or insomnia. Avoid in porphyria, severe hepatic impairment, or history of substance abuse. Contraindicated with MAOIs.
BREVITAL SODIUM is a potent anesthetic that causes rapid loss of consciousness and should only be administered by trained medical professionals.,You may experience temporary pain or burning at the injection site; report any persistent pain or swelling to your healthcare provider.,Drowsiness, dizziness, and confusion may persist for several hours after the procedure; do not drive or operate machinery for at least 24 hours.,Avoid alcohol and other sedatives for 24 hours before and after the procedure as they may increase side effects.,Inform your doctor if you have a history of porphyria, liver disease, or drug allergies.,If you are pregnant or breastfeeding, discuss the risks and benefits with your healthcare provider.
Take exactly as prescribed; do not increase dose or frequency.,Avoid alcohol while taking this medication.,Do not exceed 4000 mg acetaminophen per day from all sources.,This medication can be habit-forming; do not share with others.,May cause drowsiness; avoid driving or operating machinery until you know how it affects you.,Report signs of liver injury: yellowing skin/eyes, dark urine, abdominal pain.,Do not use for more than 5 days per week to avoid rebound headaches.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BREVITAL SODIUM vs MICRAININ, answered by our medical review team.
BREVITAL SODIUM is a Barbiturate Anesthetic that works by Brevital sodium (methohexital) is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride ion influx and hyperpolarizing neurons, leading to rapid sedation and anesthesia.. MICRAININ is a Barbiturate Combination Analgesic that works by MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BREVITAL SODIUM and MICRAININ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BREVITAL SODIUM is: Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15 seconds; maintenance: 0.5-1 mg/kg IV bolus as needed or 50-150 mcg/kg/min IV infusion.. The standard adult dose of MICRAININ is: 2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BREVITAL SODIUM and MICRAININ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BREVITAL SODIUM is classified as Category C. Teratogenic potential not fully established in humans. In animal studies, methohexital caused fetal resorptions and malformations at maternally toxic doses. First trimester: Avoid . MICRAININ is classified as Category C. MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, par. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.